Introduction
The kidneys, as a major filter organ for the blood and the key organ responsible for maintaining total body water balance and circulatory pressure, receive a rich blood supply by which they monitor and modify the functional status of multiple organ systems. Besides clearing metabolic waste products, toxins and drugs from our body, the kidneys also clear circulating cytokines and bacterial toxins like lipopolysaccharide (LPS) and continuously sample blood-borne proteins, contributing to homeostasis of the immune system. The removal of cytokines from the blood can limit inflammation [1, 2] , and the clearance of bacterial components reduces would-be immune cell activation by pattern recognition receptors (PRRs) [2, 3] . In addition, kidney resident dendritic cells (DCs) appear to be very important in maintaining peripheral tolerance [1] . As 85% of the water filtered at the glomerulus is immediately reabsorbed by the proximal tubule, cells in the distal nephron downstream experience filtered low-molecular weight antigens at concentrations up to ten times higher than in the blood itself. These antigens are taken up readily by a dense network of DCs, for example via dendrites protruding directly into the tubular lumen, enabling these filtered antigens to be presented to T cells in renal draining lymph nodes more efficiently than possible elsewhere in the body. Through this regular presentation of innocuous antigens in the absence of danger signals, potentially autoreactive T cells recognising these low molecular weight antigens are inactivated. Thus, the kidneys, in addition to the spleen, assist in maintaining peripheral tolerance to circulating antigens such as hormones and food proteins [1, 4] . The kidney's important contribution to immune homeostasis becomes especially clear in end stage renal disease (ESRD), where immune function is severely compromised. The retention of uraemic toxins and cytokines activates innate immune cells leading to a vicious cycle of further cytokine and reactive oxygen species production, both contributing to tissue damage and increasing cardiovascular risk. Additionally, lymphocyte number and function decrease, leaving the patient functionally immunocompromised and at risk of infection as well as viral-associated cancers [2, 5] .
Conversely, the kidneys themselves are also very susceptible to immune mediated diseases. Loss of immune homeostasis can adversely affect the kidney either directly or indirectly, leading to loss of kidney function. Homeostasis describes the physiological condition of a system under normal conditions. In the immune system, homeostasis therefore refers to its function and maintenance in the uninfected host [6] .
However, it could be argued that the inflammatory immune response to infections and tissue damage is a normal extension of the immune system's homeostatic function, as long as the immune response resolves. Assuming the latter definition of immune homeostasis, loss of homeostasis includes over or under activity of the immune response, but not the initial reaction to infection or tissue injury. The following is a brief overview of immune-mediated kidney disease, which in accordance with the above definition will not include congenital kidney diseases, or those caused by infections or sterile injury.
Direct immune-mediated renal disease
Renal diseases associated with loss of immune homeostasis can be grouped according to direct or indirect immune-mediated kidney injury. Direct immune-mediated renal disease involves the immune system targeting specific antigens within the kidney; while in indirect immune-mediated renal disease, the kidneys are a bystander victim of processes resulting from systemic dysregulation of the immune system. Self-antigens constituently found in the kidneys are the targets for several autoimmune diseases, which can inflict either renal limited pathology or additionally involve multiple organ systems.
Overall, disruption of immune homeostasis leads to direct renal disease through autoreactivity of both T and B cells, which can damage the kidneys at different sites. The resulting injury shows a range of histologic patterns, which correspond to various underlying mechanisms associated with specific treatment responses and renal prognosis, but the range of clinical presentations is more limited, highlighting the value of renal biopsy in patient management. Continuous insults to epithelial and interstitial cells in the kidney result in scarring and diminished renal function, thus leading to the establishment of CKD.
Direct targets of the immune system located in the glomerulus
Classic examples of direct immune-mediated renal disease where the target antigen is located in the glomerulus are anti-glomerular basement membrane disease (anti-GBM disease), and membranous glomerulonephritis (MGN), which both present clinically with glomerular abnormalities, such proteinuria and haematuria, and often progress to chronic kidney disease (CKD) and ultimately ESRD. Anti-GBM disease is a form of crescentic glomerulonephritis (GN), most often presenting with acute renal abnormalities, and in some patients also severe alveolar haemorrhage in the lungs (Goodpasture's syndrome). Circulating autoantibodies bind the NC1 domain of the collagen IV α3 chain (α3(IV)NC1) [7] . Interestingly, the epitopes recognized by this autoantibody are typically hidden within in the quaternary structure of type IV collagen, so that an initial conformational change must occur before the autoantibodies can bind.
Potential triggers for the unmasking of the autoantigen are still unknown, but once 6 binding has occurred it leads to further conformational changes and thus perpetuation of antigen-antibody complex formation [8] . [11] . It is likely that further autoantigens will be discovered as causes of primary MGN, which may turn out to be simply a collective term for autoimmune diseases targeting renal podocyte membranes.
Direct targets of the immune system located in the renal tubules and interstitium
Anti-tubular basement membrane (TBM) disease, for example, is an autoantibody mediated form of progressive primary tubulointerstitial nephritis (TIN). Damage to the TBM occurs through both autoantibody deposition and activity of autoreactive T cells against the membrane's 3M-1 glycoprotein [12] . Strong linear staining of the proximal TBM with IgG is visible with immunofluorescence microscopy. Light microscopy of these renal biopsies often shows interstitial inflammation with extensive fibrosis and small atrophic tubules [13] .
TIN can also result from primary Sjögren's syndrome (pSS), affecting about 10% of pSS patients. Although pSS is a systemic autoimmune condition characteristically affecting glandular epithelium, with renal involvement typically manifested by glomerulonephritis due to deposition of circulating immune complexes, development of TIN in pSS seems to result from a renal-directed immune process. Potential selfantigens targeted by autoantibodies and autoreactive T cells in pSS include carbonic anhydrase and the hydrogen transporter H + -ATPase, which are found in both renal tubules and salivary glands [14] . pSS-associated TIN is characterised by lymphocyte infiltration of the tubular and interstitial compartments, accompanied by a large proportion of interstitial plasma cells. Though TIN in general is associated with subsequent tubular atrophy and interstitial fibrosis, often leading to CKD, pSSassociated TIN usually takes a relatively benign course and often responds well to treatment with rituximab, a monoclonal antibody against the B cell marker CD20 [15] .
Indirect immune-mediated renal disease
As for direct immune-mediated renal disease, the majority of indirect immune-mediated renal pathologies are due to autoimmunity, but some are the consequence of genetic defects in band-like electron dense deposits of complement form along the GBM, leading to GBM thickening and dysfunction [21] . In addition to GBM deposits, C3 glomerulopathies also show varying degrees of mesangial C3 deposits, leading to mesangial cell proliferation and matrix expansion. In both DDD and C3 glomerulopathies, immunoglobulin deposits may co-localize with the complement deposits, though the immune complexes will be present in smaller proportions compared to those seen in true immune complexmediated renal diseases [1, 13, 18 ]. and capillaries by thrombotic microangiopathy, which can both lead to focal cortical atrophy or focal segmental glomerulosclerosis [24] . True immune complex-type deposits are not seen in the lesions, and injury to the renal parenchyma is mainly mediated by ischemia [22, 23] . 
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Transplantation
The immune-mediated effects on the kidney after transplantation are extraordinary. Not only is organ transplantation an artificial setting -one that the immune system was not designed to deal with in terms of tissue surveillance or peripheral tolerance [27] -the alloimmune response underlying transplant rejection is incredibly robust.
Recipient immune responses directed against the allograft can be viewed in our previous construct of direct immune-mediated renal injury resulting from loss of immune homeostasis. Allograft rejection can be mediated by alloreactive antibodies or T cells. Acute rejection typically occurs within days or weeks of transplantation, when a major immune reaction occurs. Chronic rejection on the other hand, is a slow process, during which low level immune activity causes continuous damage to the renal epithelium and vasculature leading to fibrosis and progressively declining kidney function [28] .
Antibodies and T cells target the foreign major histocompatibility complex (MHC) and
MHC-like molecules expressed on the graft endothelium and epithelium. Donorreactive T cells can be generated by pre-exposure to foreign MHC molecules, for example through a previous blood transfusion or pregnancy, by generation of pathogen-specific memory T cells cross-reactive to epitopes on donor cells, or by de novo activation of naïve T cells against graft antigens, achieved by interaction with DCs derived either from the donor graft or from the recipient. Donor-derived DCs directly activate recipient T cells via the foreign MHC that they express, regardless of the presented peptide antigen. Recipient DCs present, on self-MHC, peptides derived from donor-specific proteins and thus activate the T cells against donor cells indirectly [27] .
In addition to the multiple adaptive immune pathways that can contribute to the development of the clinical rejection, the innate immune system probably also contributes to the initiation of transplant rejection [29] . Due to these complex mechanisms and the fact that the T cells respond so strongly to allogeneic MHC molecules, current immunosuppressive therapy to prevent transplant rejection is often not 100% effective [27, 28] . Furthermore, this therapy is complicated by the side effects of immunosuppression, and a difficult balance has to be struck between immune- to be at risk not only of PTLD but also of a variety of carcinomas [31] . More specific immunosuppressive drugs are therefore required, so that a positive transplant outcome does not lead to serious malignancy.
Immune involvement in the progression of renal disease
The During acute kidney injury (AKI) following sterile tissue injury, for example after renal artery infarction or through toxins, intrarenal immune cells are activated. Damaged renal epithelial cells activate their stress response pathways, which lead to the secretion of cytokines and vasoactive factors [5] . In addition, resident macrophages and DCs are activated by danger-associated molecular patterns (DAMPs), which are released by activated renal epithelial and necrotic cells. Together the activated cells recruit further leukocytes and initiate an immune response to clear debris and necrotic tissue, before tissue repair can take place [5] . The immune response, though detrimental in the long term if sustained, is essential for the repair of tissue. Severe damage can rarely be restored, but the kidneys will often heal after moderate ischaemic injury. The mechanisms by which the immune system regulates the healing process are not fully understood. DCs, macrophages and regulatory T cells, as well as the cytokines IL-10 and IL-22, have been implicated [32, 33] . A phenotypic shift in the renal mononuclear phagocytes from the pro-inflammatory Ly6C high MRto the Ly6C low MR + anti-inflammatory associated phenotype can be observed as part of normal resolution following the initial responses to AKI (Figure 2 ) [34] . It remains uncertain how this switch is triggered.
In the absence of anti-inflammatory factors or after severe tissue damage, the immune system further contributes to the development and progression of CKD. As a consequence of any initial renal pathology, immune cells may infiltrate the damaged tissue in response to DAMPs and chemotactic factors. These cells appear to be activated in a way that does not promote healing and instead perpetuates the inflammatory process. Tissue damage also releases previously "hidden" antigens, which may be recognised by autoreactive T cells. This de novo formation of autoimmunity has been proposed as a mechanism sustaining the immune response [32] . Progressive remodelling eventually leads to tubular atrophy and interstitial scarring, which manifest clinically as worsening renal function [1] .
Treatment for AKI and CKD is supportive, with the aim of slowing the progression to ESRD, which requires renal replacement therapy. Targeted treatments have not been developed yet, and are also not available for many of the immune-mediated renal diseases. The latter are commonly treated by general immunosuppression, for example with corticosteroids. However, several of the target antigens of primary renal autoimmune diseases have been identified, meaning directed treatment could theoretically be possible. For example, a murine model of anti-GBM-disease was used to demonstrate that disease activity could be reduced by induction of mucosal tolerance through nasal administration of an immunodominant peptide from the anti-GBM target α3(IV)NC1 [35] . However, for many diseases the exact target antigen and its major epitopes are still unknown. In addition, clinical manifestation of the disease often occurs relatively late in the pathogenesis, when substantial damage has already occurred. Although knowledge of genetic susceptibility has increased, environmental factors are still essential to the initiation of autoimmune diseases, so that prophylactic treatment is not possible or feasible at this stage.
It would be interesting to determine whether or not the progression to ESRD can be stopped by a single intervention, regardless of the initial aetiology of renal disease. Perhaps the immune system itself can be harnessed to promote healing. Several studies in experimental ischaemic AKI suggest that cellular therapy with DCs and regulatory T cells could promote tissue repair [36, 37, 38] . These treatments appear effective during the initial injury, but early administration in normal clinical conditions is usually not possible [32] . Further research is therefore needed to find treatment options, which could be used in clinical practice. First steps could include further investigation of the immune responses and tissue repair in patients with AKI which does not progress to CKD. The differentiation of T cell populations might be of particular interest.
Moreover, anti-GBM disease can sometimes be self-limiting and regulatory cell populations have been described in the later phases [39] . Additional research into these T cells might further aid in the understanding of the decision point between regulatory or effector T cell activation.
To conclude, the immune system plays a central role in the initiation, progression and resolution of renal disease (summarised in Figure 3 ). Our understanding of renal resident immune cells and of the varied immune mechanisms underlying renal disease is increasing and may aid in the design of future targeted immune-based therapies to 1 8 restore homeostasis of the immune system, rather than simply suppress it, in order to promote appropriate healing and prevent progression to CKD and ESRD.
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